Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1601 in Adult Subjects With NASH
NCT05692492Phase 2Active, not recruiting
- Sponsor
- Raynovent Biotech
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zsp1601 in Nonalcoholic steatohepatitis (NASH), sponsored by Raynovent Biotech. Started Jun 2023; status: active, not recruiting.
02
Drugs
zsp1601
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05692492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692492.